Get started
Work

Supplementary Figure 3 from Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

Year: 2023
Type: supplementary-materials
Abstract: PDF file - 36K, Figure S3. Xenograft response data for 7-day tissue acquisition studies. A-C, SUM190, UACC812 and KPL-1 xenografts (6 mice per arm) were treated with BKM120 at 35 mg/kg, BYL719 at 50 mg/kg, RAD001 at 10 mg/kg and BEZ235 at 30 mg/kg, all daily PO. Trastuzumab was given at given at 10 mg/kg IP twice weekly. For SUM190 (A), tumors were collected 2.5 hours post final dose, for UACC812 (B) and KPL-1 (C), samples were collected 24 hours post final dose.
DOI: 10.1158/1078-0432.22449728
Authors: Neil A. O'Brien, Karen McDonald, Luo Tong, Erika von Euw, Ondrej Kalous, Dylan Conklin, Sara A. Hurvitz, Emmanuelle di Tomaso, Christian Schnell, Ronald Linnartz, Richard S. Finn, Samit Hirawat, Dennis J. Slamon
Language: English
Open Access status: gold
OpenAlex ID: W4361882751
Cites:
Cited by:
Related to: 10